License Agreements - AstraZeneca (Details) - AstraZeneca - USD ($)	1 Months Ended		12 Months Ended
	Aug. 31, 2019	Jul. 31, 2018	Dec. 31, 2021	Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License agreement, cash payment	$ 2,000,000	$ 1,000,000	$ 0	$ 0
Maximum milestone payments for licensed products			12,500,000
Maximum product milestone payments upon first product approval			7,500,000
Maximum milestone payments for net worldwide sales			$ 15,000,000
Series B preferred stock
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Preferred stock issued (in shares)		484,388
Preferred stock issued		$ 3,000,000